The Power Vaccinesprotecting Your Pet and the World Around You

The market for animal vaccinations is expected to reach US$ 12 billion in 2022 and grow at a positive CAGR of 9.2% to US$ 29 billion by the end of the assessment period in 2022–2032. When disease outbreaks in cattle and canine issues both rise, so do sales of immunisations for animals. The market for animal vaccinations is also benefiting from government R&D spending in various countries.

The prospects included in this section range from the capacity to produce items to the provision of retail, wholesale, and exhibition services. To arrive at various assessments and projections for the market demand for animal products, the FactMR experts conducted extensive rounds of both mandatory and optional research. vaccines. at worldwide and provincial levels.

Download a Sample Copy of This Report : – https://www.factmr.com/connectus/sample?flag=S&rep_id=7123?PJ

Market Players: –

Merck & Co. Inc.
Zoetis Inc.
Boehringer Ingelheim International GmbH
Virbac
Biogenesis Bago
Indian Immunologicals Ltd.
Elanco Animal Health Incorporated
CEVA Animal Health (Pty) Ltd.
Phibro Animal Health Corporation
NEOGEN Corporation

Key Segments Covered in the Animal Vaccines Industry Report

By Product
Attenuated Live Animal Vaccines
Recombinant Animal Vaccines
DNA Animal Vaccines
Inactivated Animal Vaccines
Subunit Animal Vaccines
By Animal Type
Livestock Animal Vaccines
Poultry
Ruminants
Swine
Aqua
Companion Animal Vaccines
Canine
Feline
Others
By Route of Administration
Subcutaneous Administration of Animal Vaccines
Intranasal Administration of Animal Vaccines
Intramuscular Administration of Animal Vaccines

Regional analysis includes

North America (US, Canada)
Latin America (Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM)
EU – (Germany, France, Italy, Spain), UK, BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
CIS & Russia
Japan
Asia Pacific Excluding Japan (Greater China, India, S. Korea, ASEAN Countries, Rest of APEJ)

Competitive Landscape

Prominent manufacturers of animal vaccines are capitalizing on increasing government support across countries to promote animal health. This support is translating into the introduction of robust vaccine formulations against a wide variety of pathogens. Moreover, players are emphasizing on mergers, acquisitions and collaborations to secure firm footing in this highly competitive environment. Some notable developments are as follows:

In August 2020, Merck & Co., Inc. completed the acquisition of IdentiGEN. The company is focusing on studying DNA of animals for livestock. Through this acquisition, Merck intends to provide complete transparency to food processors, producers and retailers, regarding animal traceability solutions to ensure that good quality food is available to consumers
In January 2022, Zoetis Inc. announced that the US Food and Drug Administration has approved SolensiaTM (frunevetmab injection) to control the pain of osteoarthritis in cats, helping improve their mobility, comfort and overall well-being. The injection works by directly targeting the Nerve Growth Factor (NGF), a key OA pain driver

Frequent Disease Outbreaks Bolstering Demand for Animal Vaccinations

Growing prevalence of zoonotic diseases have the potential to negatively impact human lives. Moreover, increasing population of both humans has given a rise to the transmission of pathogens within and between species. In addition, emerging and exotic animal diseases are a growing threat to human and animal health.

Improved demand for animal protein has resulted in increased commercial food animal production. Emerging zoonotic diseases of both companion and livestock animals are a major threat to public health. Furthermore, the possibility of world experiencing emerging disease outbreaks is high. Thus, the demand for vaccinating animals has increased.